The Effect of Amiloride and Spironolactone in Patients With Hypertension

Erling Bjerregaard Pedersen23 enrolled

Overview

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone. The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Purpose of the study is to examine the effect of amilorid and spironolacton on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewavevelocity, augmentation index and centralt bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory blood pressure

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypertension

Interventions

SpironolactoneDRUG

25 mg twice a day

AmilorideDRUG

5 mg twice a day

PlaceboDRUG

twice a day

Eligibility

Sex: ALLMin age: 45 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertension * Age 45-70 * BMI: 18,5-30 Exclusion Criteria: * Other diseases * Drug or alcohol abuse * Abnormal findings in the screening procedure

Locations (1)

Department of Medical Research

Holstebro, Denmark

Outcomes

Primary Outcomes

Blood pressure

24 hours blood pressure measurements

Time frame: 2 years

Secondary Outcomes

Pulse wave velocity

We will investigate the changes in cardiovascular variables using a Sphygmocor scanner.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.